Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia

R. Hashimoto, H. Hashimoto, N. Shintani, S. Chiba, Satoko Takai, T. Okada, M. Nakajima, K. Tanaka, N. Kawagishi, K. Nemoto, T. Mori, T. Ohnishi, H. Noguchi, H. Hori, T. Suzuki, Nakao Iwata, N. Ozaki, T. Nakabayashi, O. Saitoh, A. KosugaM. Tatsumi, K. Kamijima, D. R. Weinberger, H. Kunugi, A. Baba

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.

Original languageEnglish
Pages (from-to)1026-1032
Number of pages7
JournalMolecular Psychiatry
Volume12
Issue number11
DOIs
Publication statusPublished - 01-11-2007

Fingerprint

Pituitary Adenylate Cyclase-Activating Polypeptide
Schizophrenia
Genes
Startle Reflex
Pituitary Adenylate Cyclase-Activating Polypeptide Receptors
Risperidone
Locomotion
Neuropeptides
Adenylyl Cyclases
Knockout Mice
Synaptic Transmission
Antipsychotic Agents
Alleles
Peptides

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Hashimoto, R., Hashimoto, H., Shintani, N., Chiba, S., Takai, S., Okada, T., ... Baba, A. (2007). Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Molecular Psychiatry, 12(11), 1026-1032. https://doi.org/10.1038/sj.mp.4001982
Hashimoto, R. ; Hashimoto, H. ; Shintani, N. ; Chiba, S. ; Takai, Satoko ; Okada, T. ; Nakajima, M. ; Tanaka, K. ; Kawagishi, N. ; Nemoto, K. ; Mori, T. ; Ohnishi, T. ; Noguchi, H. ; Hori, H. ; Suzuki, T. ; Iwata, Nakao ; Ozaki, N. ; Nakabayashi, T. ; Saitoh, O. ; Kosuga, A. ; Tatsumi, M. ; Kamijima, K. ; Weinberger, D. R. ; Kunugi, H. ; Baba, A. / Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. In: Molecular Psychiatry. 2007 ; Vol. 12, No. 11. pp. 1026-1032.
@article{5629e471a2534c018a128a57263f45e0,
title = "Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia",
abstract = "Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.",
author = "R. Hashimoto and H. Hashimoto and N. Shintani and S. Chiba and Satoko Takai and T. Okada and M. Nakajima and K. Tanaka and N. Kawagishi and K. Nemoto and T. Mori and T. Ohnishi and H. Noguchi and H. Hori and T. Suzuki and Nakao Iwata and N. Ozaki and T. Nakabayashi and O. Saitoh and A. Kosuga and M. Tatsumi and K. Kamijima and Weinberger, {D. R.} and H. Kunugi and A. Baba",
year = "2007",
month = "11",
day = "1",
doi = "10.1038/sj.mp.4001982",
language = "English",
volume = "12",
pages = "1026--1032",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "11",

}

Hashimoto, R, Hashimoto, H, Shintani, N, Chiba, S, Takai, S, Okada, T, Nakajima, M, Tanaka, K, Kawagishi, N, Nemoto, K, Mori, T, Ohnishi, T, Noguchi, H, Hori, H, Suzuki, T, Iwata, N, Ozaki, N, Nakabayashi, T, Saitoh, O, Kosuga, A, Tatsumi, M, Kamijima, K, Weinberger, DR, Kunugi, H & Baba, A 2007, 'Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia', Molecular Psychiatry, vol. 12, no. 11, pp. 1026-1032. https://doi.org/10.1038/sj.mp.4001982

Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. / Hashimoto, R.; Hashimoto, H.; Shintani, N.; Chiba, S.; Takai, Satoko; Okada, T.; Nakajima, M.; Tanaka, K.; Kawagishi, N.; Nemoto, K.; Mori, T.; Ohnishi, T.; Noguchi, H.; Hori, H.; Suzuki, T.; Iwata, Nakao; Ozaki, N.; Nakabayashi, T.; Saitoh, O.; Kosuga, A.; Tatsumi, M.; Kamijima, K.; Weinberger, D. R.; Kunugi, H.; Baba, A.

In: Molecular Psychiatry, Vol. 12, No. 11, 01.11.2007, p. 1026-1032.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia

AU - Hashimoto, R.

AU - Hashimoto, H.

AU - Shintani, N.

AU - Chiba, S.

AU - Takai, Satoko

AU - Okada, T.

AU - Nakajima, M.

AU - Tanaka, K.

AU - Kawagishi, N.

AU - Nemoto, K.

AU - Mori, T.

AU - Ohnishi, T.

AU - Noguchi, H.

AU - Hori, H.

AU - Suzuki, T.

AU - Iwata, Nakao

AU - Ozaki, N.

AU - Nakabayashi, T.

AU - Saitoh, O.

AU - Kosuga, A.

AU - Tatsumi, M.

AU - Kamijima, K.

AU - Weinberger, D. R.

AU - Kunugi, H.

AU - Baba, A.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.

AB - Pituitary adenylate cyclase-activating polypeptide (PACAP, ADCYAP1: adenylate cyclase-activating polypeptide 1), a neuropeptide with neurotransmission modulating activity, is a promising schizophrenia candidate gene. Here, we provide evidence that genetic variants of the genes encoding PACAP and its receptor, PAC1, are associated with schizophrenia. We studied the effects of the associated polymorphism in the PACAP gene on neurobiological traits related to risk for schizophrenia. This allele of the PACAP gene, which is overrepresented in schizophrenia patients, was associated with reduced hippocampal volume and poorer memory performance. Abnormal behaviors in PACAP knockout mice, including elevated locomotor activity and deficits in prepulse inhibition of the startle response, were reversed by treatment with an atypical antipsychotic, risperidone. These convergent data suggest that alterations in PACAP signaling might contribute to the pathogenesis of schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=35548965980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35548965980&partnerID=8YFLogxK

U2 - 10.1038/sj.mp.4001982

DO - 10.1038/sj.mp.4001982

M3 - Article

C2 - 17387318

AN - SCOPUS:35548965980

VL - 12

SP - 1026

EP - 1032

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 11

ER -